Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection

World Journal of Gastroenterology

Volumn 13, Issue 30, 2007, Pages 4103-4107

  Rajkumar, J S ^a   Sekar, M G ^a   Mitra, S K ^b  

^a Lifeline Rigid Hospitals   (India)

^b Himalaya Health Care   (India)

Author keywords

Chronic hepatitis B; Clinical trial; Hapatitis B Virus markers; HBeAG; HBsAG; HD 03 ES; Liver function tests

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYPERUS ROTUNDUS EXTRACT; CYPERUS SCARIOSUS EXTRACT; ES; HD 03; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PLANT EXTRACT; UNCLASSIFIED DRUG; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CYPERUS; CYPERUS SCARIOSUS; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INSOMNIA; LIVER FUNCTION TEST; MALE; MEDICINAL PLANT; NAUSEA; PILOT STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 34548237340     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i30.4103     Document Type: Article

References (17)

1. Asmuth DM, Nguyen HH, Melcher GP, Cohen SH, Pollard RB. Treatments for hepatitis B. Clin Infect Dis 2004; 39: 1353-1362
2. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 49-56
3. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094
4. De S, Ravishankar B, Bhavsar GC. Plants with hepatoprotective activity: A review. Ind Drugs 1993; 30: 355-363
5. Kulkarni KS, Dixit MN, Bhagwat, V.G, Meru AK, Babu UV, Ekta Saxena, Mitra SK. Reduction of HBsAg with decrease in viral load with herbal formulation, HD-03/ES: A case study. Med Update 2002; 7: 61-63
6. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956
7. Sakuma K, Takahara T, Okuda K, Tsuda F, Mayumi M. Prognosis of hepatitis B virus surface antigen carriers in relation to routine liver function tests: a prospective study. Gastroenterology 1982; 83: 114-117
8. Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol 2006; 101 Suppl 1: S13-S18
9. Yuen MF, Lai CL. Current and future antiviral agents for chronic hepatitis B. J Antimicrob Chemother 2003; 51: 481-485
10. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
11. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303
12. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851
13. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-306
14. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270
15. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424
16. Peng J, Luo K, Zhu Y, Guo Y, Zhang L, Hou J. Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. Chin Med J (Engl) 2003; 116: 1312-1317
17. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816